Biosimilar Cyltezo shows equivalence to mega-blockbuster Humira

12 September 2018

As AbbVie (NYSE: ABBV) continues to fend of biosimilars competition in the USA for to its mega-blockbuster drug Humira (adalimumab), new data presented at the European Association of Dermatology and Venereology Annual Meeting (EADV 2018) in Paris further support another strong competitor.

Boehringer Ingelheim today announced results from a Phase III study, confirming that Cyltezo (adalimumab-adbm) is equivalent to Humira, with no clinically meaningful differences in efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis.

Cyltezo was approved by the US Food and Drug Administration in August last year, not yet marketed as Boehringer is currently engaged in patent litigation with AbbVie in the USA. It was also approved by the European Medicines Agency in November 2017. Humira’s global sales in the second quarter of 2018 were up 10% year-on-year at $5.2 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK